Evidence map›Paper›PMID 37545746›Full record

ArticleLancet regional health. Americas2023

Patterns of care in the management of high-risk COPD in the US (2011-2019): an observational study for the CONQUEST quality improvement program.

Margee Kerr, Yasir Tarabichi, Alexander Evans, Douglas Mapel, Wilson Pace, Victoria Carter, Amy Couper, M Bradley Drummond, Norbert Feigler, Alex Federman and 16 more

Abstract read
In one paragraph

Article in Lancet regional health. Americas, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. A Syndemic Model: COPD, Multimorbidity, and Poverty.Chronic obstructive pulmonary diseases (Miami, Fla.) · 2024
    Article
  7. Article
  8. Risk of Death and Cardiovascular Events Following an Exacerbation of COPD: The EXACOS-CV US Study.International journal of chronic obstructive pulmonary disease · 2024
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

26 authors.

Margee KerrObservational and Pragmatic Research Institute, Singapore, Singapore.
Yasir TarabichiCenter for Clinical Informatics Research and Education, MetroHealth, Cleveland, OH, USA.
Alexander EvansOptimum Patient Care, Cambridge, UK.
Douglas MapelUniversity of New Mexico College of Pharmacy, Albuquerque, NM, USA.
Wilson PaceDARTNet Institute, Aurora, USA.
Victoria CarterOptimum Patient Care, Cambridge, UK.
Amy CouperObservational and Pragmatic Research Institute, Singapore, Singapore.
M Bradley DrummondDivision of Pulmonary Diseases and Critical Care Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA.
Norbert FeiglerBioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA.
Alex FedermanGeneral Internal Medicine, Mount Sinai, New York, NY, USA.
Hitesh GandhiBioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA.
Nicola A HananiaSection of Pulmonary and Critical Care Medicine, and Director of the Airways Clinical Research Center, Baylor College of Medicine, Houston, TX, USA.
Alan KaplanObservational and Pragmatic Research Institute, Singapore, Singapore.
Konstantinos KostikasRespiratory Medicine Department, University of Ioannina, Ioannina, Greece.
Maja KruszykObservational and Pragmatic Research Institute, Singapore, Singapore.
Marije van MelleObservational and Pragmatic Research Institute, Singapore, Singapore.
Hana MüllerováBioPharmaceuticals Medical, AstraZeneca, Cambridge, UK.
Ruth MurrayOptimum Patient Care, Cambridge, UK.
Jill OharDepartment of Internal Medicine, WakeForest University, Winston-Salem, NC, USA.
Michael PollackBioPharmaceuticals Medical, AstraZeneca, Wilmington, DE, USA.
Rachel PullenObservational and Pragmatic Research Institute, Singapore, Singapore.
Dennis WilliamsUNC Eshelman School of Pharmacy, Chapel Hill, NC, USA.
Juan WisniveskyGeneral Internal Medicine, Mount Sinai, New York, NY, USA.
MeiLan K HanUniversity of Michigan, Ann Arbor, MI, USA.
Catherine MeldrumDivision of Pulmonary & Critical Care at University of Michigan Hospital, Ann Arbor, MI, USA.
David PriceObservational and Pragmatic Research Institute, Singapore, Singapore.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: In this study, we compare management of patients with high-risk chronic obstructive pulmonary disease (COPD) in the United States to national and international guidelines and quality standards, including the COllaboratioN on QUality improvement initiative for achieving Excellence in STandards of COPD care (CONQUEST). Methods: Patients were identified from the DARTNet Practice Performance Registry and categorized into three high-risk cohorts in each year from 2011 to 2019: newly diagnosed (≤12 months after diagnosis), already diagnosed, and patients with potential undiagnosed COPD. Patients were considered high-risk if they had a history of exacerbations or likely exacerbations (respiratory consult with prescribed medication). Descriptive statistics for 2019 are reported, along with annual trends. Findings: In 2019, 10% (n = 16,610/167,197) of patients met high-risk criteria. Evidence of spirometry for diagnosis was low; in 2019, 81% (n = 1228/1523) of patients newly diagnosed at high-risk had no record of spirometry/peak expiratory flow in the 12 months pre- or post-diagnosis and 43% (n = 651/1523) had no record of COPD symptom review. Among those newly and already diagnosed at high-risk, 52% (n = 4830/9350) had no evidence of COPD medication. Interpretation: Findings suggest inconsistent adherence to evidence-based guidelines, and opportunities to improve identification, documentation of services, assessment, therapeutic intervention, and follow-up of patients with COPD. Funding: This study was conducted by the Observational and Pragmatic Research Institute (OPRI) Pte Ltd and was partially funded by Optimum Patient Care Global and AstraZeneca Ltd. No funding was received by the Observational & Pragmatic Research Institute Pte Ltd (OPRI) for its contribution.

Indexed as

Coordination of careCOPDDiagnosisExacerbationsSpirometryTreatment

Identifiers

PMID37545746
PMCPMC10400879

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.